Amantadine in Huntington's disease: open-label video-blinded study
Purchase on Springer.com
$39.95 / €34.95 / £29.95*
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.
Huntington's disease (HD) is characterized by chorea, cognitive and behavioral changes. Amantadine, a non-competitive NMDA receptor antagonist, has shown an antidyskinetic effect on levodopa-induced dyskinesias, which are known to have strict pathogenetic analogies with choreic hyperkinesias. The antidyskinetic efficacy of amantadine and its effects on cognitive and behavioural symptoms were evaluated. Eight HD patients received oral amantadine (100 mg tid) unblinded for a 1-year period. A significant reduction of dyskinesias was reported (p<0.01). No changes were observed in neuropsychologic and psychiatric assessments after 6 and 12 months of therapy. These data may have relevance to the treatment of HD with amantadine.
- Amantadine in Huntington's disease: open-label video-blinded study
Volume 23, Issue 2 Supplement, pp s83-s84
- Cover Date
- Print ISSN
- Online ISSN
- Springer-Verlag Italia
- Additional Links
- Author Affiliations
- A1. Department of Neuroscience, University of Pisa, Pisa, Italy, IT
- A2. Epidemiology and Biostatistics Unit, Institute of Clinical Physiology, CNR, Pisa, Italy, IT